Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHARLES ROGERS

Allopathic & Osteopathic Physicians Obstetrics & Gynecology

NPI
1073619078
CMS profile
93456
Location
MOBILE, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$147.77

11 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $147.77 11

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
AbbVie Inc. $58.19 4
Astellas Pharma US Inc $26.66 2
Radius Health, Inc. $17.59 1
Mission Pharmacal Company $13.08 1
TherapeuticsMD, Inc. $11.41 1
Novo Nordisk Inc $11.32 1
PFIZER INC. $9.52 1

Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHARLES ROGERS

NPI 1073619078 · CMS profile ID 93456

Allopathic & Osteopathic Physicians / Obstetrics & Gynecology

MOBILE, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1073619078?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHARLES ROGERS, NPI 1073619078, CMS profile ID 93456. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1073619078?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). CHARLES ROGERS, NPI 1073619078, CMS profile ID 93456. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1073619078?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
CHARLES ROGERS, NPI 1073619078, CMS profile ID 93456, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1073619078?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

11 matching records · $147.77 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 11 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–11 of 11.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie Inc. $19.7712/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722099357 CMS
AbbVie Inc. $13.8311/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722099355 CMS
TherapeuticsMD, Inc. $11.4110/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 745713731 CMS
Astellas Pharma US Inc $13.0110/26/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718375517 CMS
Radius Health, Inc. $17.5910/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 746295163 CMS
AbbVie Inc. $11.8510/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722099353 CMS
Novo Nordisk Inc $11.3207/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744779327 CMS
Mission Pharmacal Company $13.0803/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 712452107 CMS
PFIZER INC. $9.5203/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743331391 CMS
AbbVie Inc. $12.7401/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722099351 CMS
Astellas Pharma US Inc $13.6501/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718375515 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $211.89 14
PY2020 $147.77 11
PY2021 $367.33 25
PY2022 $191.74 15
PY2023 $50.47 4
PY2024 $23.32 1
PY2025 $1,567.18 5

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2023 Principal investigator $64,452.88 14
PY2022 Principal investigator $698,324.95 119
PY2021 Principal investigator $841,564.46 110
PY2020 Principal investigator $209,720.80 9

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

119 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $19,892.40 12/30/2022 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949773357
Principal investigator 1 PFIZER INC. $16,502.80 12/16/2022 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 12 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT GROUP B STREPTOCOCCUS VACCINE IN HEALTHY NONPREGNANT WOMEN AND PREGNANT WOMEN 18 TO 40 YEARS OF AGE AND THEIR INFANTS No dispute reported 06/30/2026 949773187
Principal investigator 1 GlaxoSmithKline, LLC. $579.15 12/07/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978031
Principal investigator 1 PFIZER INC. $6,098.40 12/07/2022 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949773185
Principal investigator 1 PFIZER INC. $4,210.80 12/06/2022 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949774037
Principal investigator 1 GlaxoSmithKline, LLC. $965.25 11/23/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978453
Principal investigator 1 GlaxoSmithKline, LLC. $882.09 11/09/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978287
Principal investigator 1 GlaxoSmithKline, LLC. $1,365.21 11/09/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978335
Principal investigator 1 GlaxoSmithKline, LLC. $772.20 11/09/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978475
Principal investigator 1 PFIZER INC. $4,210.80 11/05/2022 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949782049
Principal investigator 1 PFIZER INC. $4,066.89 11/05/2022 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 12 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT GROUP B STREPTOCOCCUS VACCINE IN HEALTHY NONPREGNANT WOMEN AND PREGNANT WOMEN 18 TO 40 YEARS OF AGE AND THEIR INFANTS No dispute reported 06/30/2026 949782093
Principal investigator 1 GlaxoSmithKline, LLC. $1,544.40 10/25/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978133
Principal investigator 1 GlaxoSmithKline, LLC. $1,075.14 10/25/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978529
Principal investigator 1 PFIZER INC. $39,838.10 10/25/2022 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949795811
Principal investigator 1 GlaxoSmithKline, LLC. $1,075.14 10/12/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978281
Principal investigator 1 GlaxoSmithKline, LLC. $1,268.19 10/12/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978523
Principal investigator 1 GlaxoSmithKline, LLC. $1,075.14 10/03/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978329
Principal investigator 1 GlaxoSmithKline, LLC. $965.25 10/03/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978369
Principal investigator 1 GlaxoSmithKline, LLC. $2,207.70 09/27/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978157
Principal investigator 1 PFIZER INC. $14,500.00 09/23/2022 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 12 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT GROUP B STREPTOCOCCUS VACCINE IN HEALTHY NONPREGNANT WOMEN AND PREGNANT WOMEN 18 TO 40 YEARS OF AGE AND THEIR INFANTS No dispute reported 06/30/2026 949796493
Principal investigator 1 PFIZER INC. $15,793.80 09/22/2022 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949796699
Principal investigator 1 GlaxoSmithKline, LLC. $3,533.31 09/14/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978223
Principal investigator 1 GlaxoSmithKline, LLC. $193.05 09/14/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978317
Principal investigator 1 GlaxoSmithKline, LLC. $495.99 09/14/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978323
Principal investigator 1 GlaxoSmithKline, LLC. $1,365.21 09/14/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978435
Principal investigator 1 PFIZER INC. $13,701.60 09/02/2022 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949796701
Principal investigator 1 GlaxoSmithKline, LLC. $600.00 09/01/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978163
Principal investigator 1 GlaxoSmithKline, LLC. $1,075.14 09/01/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978228
Principal investigator 1 GlaxoSmithKline, LLC. $772.20 09/01/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978253
Principal investigator 1 GlaxoSmithKline, LLC. $579.15 09/01/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978481
Principal investigator 1 GlaxoSmithKline, LLC. $13,094.73 08/17/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978079
Principal investigator 1 GlaxoSmithKline, LLC. $1,172.16 08/17/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978351
Principal investigator 1 PFIZER INC. $25,238.40 08/05/2022 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949801283
Principal investigator 1 GlaxoSmithKline, LLC. $16,000.00 08/01/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978217
Principal investigator 1 PFIZER INC. $20,024.40 07/09/2022 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949808463
Principal investigator 1 PFIZER INC. $12,474.00 06/24/2022 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949812025
Principal investigator 1 PFIZER INC. $10,682.10 06/07/2022 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949812027
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 06/03/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, OPEN-LABEL, ACTIVE VACCINE-CONTROLLED CROSSOV No dispute reported 06/30/2026 943978533
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 06/03/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, OPEN-LABEL, ACTIVE VACCINE-CONTROLLED CROSSOV No dispute reported 06/30/2026 943978539
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 06/03/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, OPEN-LABEL, ACTIVE VACCINE-CONTROLLED CROSSOV No dispute reported 06/30/2026 943978545
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 06/03/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, OPEN-LABEL, ACTIVE VACCINE-CONTROLLED CROSSOV No dispute reported 06/30/2026 943978551
Principal investigator 1 GlaxoSmithKline, LLC. $6,500.00 06/03/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, OPEN-LABEL, ACTIVE VACCINE-CONTROLLED CROSSOV No dispute reported 06/30/2026 943978557
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 06/03/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, OPEN-LABEL, ACTIVE VACCINE-CONTROLLED CROSSOV No dispute reported 06/30/2026 943978563
Principal investigator 1 GlaxoSmithKline, LLC. $1,800.00 06/03/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, OPEN-LABEL, ACTIVE VACCINE-CONTROLLED CROSSOV No dispute reported 06/30/2026 943978569
Principal investigator 1 GlaxoSmithKline, LLC. $869.22 05/25/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978241
Principal investigator 1 GlaxoSmithKline, LLC. $1,132.56 05/25/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978429
Principal investigator 1 GlaxoSmithKline, LLC. $2,563.11 05/25/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978517
Principal investigator 1 PFIZER INC. $38,006.10 05/21/2022 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949753701
Principal investigator 1 GlaxoSmithKline, LLC. $1,737.45 05/11/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978037
Principal investigator 1 GlaxoSmithKline, LLC. $308.88 05/11/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVA No dispute reported 06/30/2026 943978045
Principal investigator 1 GlaxoSmithKline, LLC. $1,132.56 05/11/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978055
Principal investigator 1 GlaxoSmithKline, LLC. $308.88 05/11/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVA No dispute reported 06/30/2026 943978269
Principal investigator 1 GlaxoSmithKline, LLC. $1,132.56 05/11/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978303
Principal investigator 1 GlaxoSmithKline, LLC. $1,055.34 05/11/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVA No dispute reported 06/30/2026 943978417
Principal investigator 1 GlaxoSmithKline, LLC. $1,866.15 05/11/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978447
Principal investigator 1 GlaxoSmithKline, LLC. $965.25 05/11/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978493
Principal investigator 1 GlaxoSmithKline, LLC. $1,075.14 04/25/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978013
Principal investigator 1 GlaxoSmithKline, LLC. $1,751.31 04/25/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978025
Principal investigator 1 GlaxoSmithKline, LLC. $1,558.26 04/25/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978051
Principal investigator 1 GlaxoSmithKline, LLC. $386.10 04/25/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978085
Principal investigator 1 GlaxoSmithKline, LLC. $3,211.56 04/25/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978098
Principal investigator 1 GlaxoSmithKline, LLC. $1,132.56 04/25/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978109
Principal investigator 1 GlaxoSmithKline, LLC. $1,365.21 04/25/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978115
Principal investigator 1 GlaxoSmithKline, LLC. $1,544.40 04/25/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978139
Principal investigator 1 GlaxoSmithKline, LLC. $2,895.75 04/25/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978151
Principal investigator 1 GlaxoSmithKline, LLC. $3,129.39 04/25/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978205
Principal investigator 1 GlaxoSmithKline, LLC. $193.05 04/25/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978257
Principal investigator 1 GlaxoSmithKline, LLC. $579.15 04/25/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978293
Principal investigator 1 GlaxoSmithKline, LLC. $617.76 04/25/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVA No dispute reported 06/30/2026 943978297
Principal investigator 1 GlaxoSmithKline, LLC. $2,053.26 04/25/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978309
Principal investigator 1 GlaxoSmithKline, LLC. $4,113.45 04/25/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978375
Principal investigator 1 GlaxoSmithKline, LLC. $772.20 04/25/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978441
Principal investigator 1 PFIZER INC. $3,405.60 04/22/2022 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949817577
Principal investigator 1 PFIZER INC. $33,983.40 04/08/2022 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949817575
Principal investigator 1 GlaxoSmithKline, LLC. $1,312.74 04/06/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVA No dispute reported 06/30/2026 943978019
Principal investigator 1 GlaxoSmithKline, LLC. $308.88 04/06/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVA No dispute reported 06/30/2026 943978341
Principal investigator 1 GlaxoSmithKline, LLC. $2,619.54 03/23/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943977989
Principal investigator 1 GlaxoSmithKline, LLC. $308.88 03/23/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVA No dispute reported 06/30/2026 943978145
Principal investigator 1 GlaxoSmithKline, LLC. $1,718.64 03/23/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978393
Principal investigator 1 GlaxoSmithKline, LLC. $308.88 03/23/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVA No dispute reported 06/30/2026 943978405
Principal investigator 1 GlaxoSmithKline, LLC. $1,268.19 03/16/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978387
Principal investigator 1 GlaxoSmithKline, LLC. $4,440.15 03/16/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978399
Principal investigator 1 GlaxoSmithKline, LLC. $700.00 03/09/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978001
Principal investigator 1 GlaxoSmithKline, LLC. $1,834.47 03/09/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978175
Principal investigator 1 GlaxoSmithKline, LLC. $2,779.92 03/09/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978187
Principal investigator 1 GlaxoSmithKline, LLC. $9,307.98 03/09/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVA No dispute reported 06/30/2026 943978381
Principal investigator 1 GlaxoSmithKline, LLC. $193.05 03/09/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978411
Principal investigator 1 GlaxoSmithKline, LLC. $1,055.34 03/09/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVA No dispute reported 06/30/2026 943978511
Principal investigator 1 PFIZER INC. $72,271.65 03/04/2022 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949826499
Principal investigator 1 GlaxoSmithKline, LLC. $1,242.45 02/22/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978007
Principal investigator 1 GlaxoSmithKline, LLC. $4,176.81 02/22/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978103
Principal investigator 1 GlaxoSmithKline, LLC. $1,737.45 02/22/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978127
Principal investigator 1 GlaxoSmithKline, LLC. $5,047.02 02/22/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978197
Principal investigator 1 GlaxoSmithKline, LLC. $1,461.24 02/22/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978457
Principal investigator 1 GlaxoSmithKline, LLC. $1,203.84 02/22/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978487
Principal investigator 1 GlaxoSmithKline, LLC. $3,855.06 02/22/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978505
Principal investigator 1 GlaxoSmithKline, LLC. $1,203.84 02/09/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943977995
Principal investigator 1 GlaxoSmithKline, LLC. $1,378.08 02/09/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978073
Principal investigator 1 GlaxoSmithKline, LLC. $1,861.20 02/09/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978091
Principal investigator 1 GlaxoSmithKline, LLC. $2,645.28 02/09/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVA No dispute reported 06/30/2026 943978121
Principal investigator 1 GlaxoSmithKline, LLC. $495.99 02/09/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978169
Principal investigator 1 GlaxoSmithKline, LLC. $2,316.60 02/09/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978235
Principal investigator 1 GlaxoSmithKline, LLC. $2,356.20 02/09/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978247
Principal investigator 1 GlaxoSmithKline, LLC. $579.15 02/09/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978463
Principal investigator 1 PFIZER INC. $113,346.09 01/25/2022 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949831333
Principal investigator 1 GlaxoSmithKline, LLC. $1,544.40 01/24/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978061
Principal investigator 1 GlaxoSmithKline, LLC. $2,123.55 01/24/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978067
Principal investigator 1 GlaxoSmithKline, LLC. $193.05 01/24/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978181
Principal investigator 1 GlaxoSmithKline, LLC. $19,002.06 01/24/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVA No dispute reported 06/30/2026 943978211
Principal investigator 1 GlaxoSmithKline, LLC. $3,642.21 01/24/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978263
Principal investigator 1 GlaxoSmithKline, LLC. $3,501.63 01/24/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978275
Principal investigator 1 GlaxoSmithKline, LLC. $1,261.26 01/24/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978347
Principal investigator 1 GlaxoSmithKline, LLC. $1,325.61 01/24/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978363
Principal investigator 1 GlaxoSmithKline, LLC. $2,756.16 01/24/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978423
Principal investigator 1 GlaxoSmithKline, LLC. $3,777.84 01/24/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978470
Principal investigator 1 GlaxoSmithKline, LLC. $6,500.00 01/24/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVA No dispute reported 06/30/2026 943978499
Principal investigator 1 PFIZER INC. $14,826.67 01/11/2022 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949831331
Principal investigator 1 GlaxoSmithKline, LLC. $200.00 01/05/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943978191
Principal investigator 1 GlaxoSmithKline, LLC. $2,800.00 01/05/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVA No dispute reported 06/30/2026 943978357